Isomorphic Labs has entered preliminary discussions to raise fresh capital at a valuation of at least $40 billion. The company, which uses machine learning to identify drug candidates, began as an internal project at Google DeepMind before operating as a distinct Alphabet subsidiary. The reported valuation target arrives while the firm has yet to bring any drug to market.
The Reported Talks
Bloomberg Technology disclosed the funding discussions on October 8, 2026. People familiar with the matter described the conversations as early and noted that the $40 billion figure represents a minimum threshold under consideration. No information on round size, lead investors, or timing has been released.
Background Within Alphabet
Isomorphic Labs was created to apply the same scaling principles that advanced protein-structure prediction at DeepMind to the broader task of small-molecule and biologic design. After the spinout, Alphabet retained majority ownership while granting the unit greater freedom to form external partnerships with pharmaceutical companies. The current talks would mark the first major external financing round since that separation.
Market Context for AI Drug Platforms
Several other AI-focused discovery firms have raised capital in recent years at valuations ranging from hundreds of millions to low single-digit billions. Those rounds typically occurred after the companies demonstrated early clinical candidates or signed large collaboration deals. A $40 billion mark would place Isomorphic Labs well above that group even though its pipeline remains preclinical.
Why it matters
A valuation at this level would establish a new reference point for the entire sector. Investors appear willing to price future revenue from AI-designed drugs at multiples previously attached only to companies with approved products and sales. That pricing carries direct consequences for partnership negotiations: pharmaceutical firms that have already signed deals with Isomorphic Labs may face higher milestone payments or equity demands in any follow-on work. Companies still evaluating collaboration will have to decide whether the technology justifies terms calibrated to a $40 billion enterprise.
For Alphabet the round would crystallize the value of its DeepMind research lineage outside its core search and cloud businesses. Continued majority ownership would give the parent continued influence over how Isomorphic Labs allocates resources between internal programs and commercial contracts. At the same time, bringing in outside capital could reduce future cash calls on Alphabet while introducing new shareholders who expect clear paths to liquidity.
The signal extends beyond Isomorphic Labs itself. Other AI drug-discovery startups will likely cite the round when setting their own targets, affecting hiring, retention of computational talent, and the structure of academic collaborations. Research priorities inside those firms may shift toward targets that can be advanced quickly enough to support the higher valuation narrative. Conversely, if the talks stall or close materially below $40 billion, the episode would serve as a caution that capital markets remain selective even in AI-adjacent life sciences.
The outcome will also test whether large-scale machine-learning models can shorten the time from target identification to clinical proof-of-concept enough to justify current pricing. Until that evidence appears in the form of approved medicines or substantial royalty streams, the $40 billion figure rests on forward-looking assumptions about model performance and deal flow.
---
Sources:
{
"publisher": "Bloomberg Technology",
"title": "Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value",
"url": "https://www.bloomberg.com/news/articles/2026-10-08/alphabet-s-isomorphic-labs-in-funding-talks-for-at-least-40-billion-value",
"published_at": "2026-10-08T04:00:00.000Z",
"summary": "Isomorphic Labs, an AI-powered drug discovery startup spun out of Alphabet Inc.’s Google DeepMind, is in early talks to raise new funds at a valuation of at least $40 billion, according to people familiar with the effort."
}
No comments yet